Angiosarcoma of the breast: a new therapeutic approach?  by Benevento, Raffaella et al.
CASE REPORT – OPEN ACCESS
International Journal of Surgery Case Reports 13 (2015) 30–32
Contents lists available at ScienceDirect
International Journal of Surgery Case Reports
journa l homepage: www.caserepor ts .com
Angiosarcoma of the breast: a new therapeutic approach?
Raffaella Benevento ∗, Francesco Carafa, Domenico Di Nardo, Gianluca Pellino,
Antonia Letizia, Marianna Taddeo, Antonio Gambardella, Silvestro Canonico,
Antonio Santoriello
Department of Medical, Surgical, Neurologic, Metabolic and Ageing Sciences, Second University of Naples, Naples, Italy
a r t i c l e i n f o
Article history:
Received 24 March 2015
Accepted 2 June 2015
Available online 6 June 2015
Keywords:
Angiosarcoma
Electrochemotherapy
Breast
a b s t r a c t
INTRODUCTION: Angiosarcomas are highly malignant endothelial cell tumors with poor prognosis. These
can be due to breast cancer itself or to subsequent therapeutic modalities. No evidence-based guidelines
exist concerning the ideal treatment of angiosarcomas.
PRESENTATION OF THE CASE: We report the case of a 76-year-old woman who developed an exuberant
and aggressive post radiation angiosarcoma of the breast and discuss different aspects of therapy for
this disease. A total left mastectomy was performed, followed by a right mastectomy. The lesions into
the chest wall, and multiple abdominal skin nodules were treated with local Electrochemotherapy (ECT)
with intravenous bleomicin.
DISCUSSION: No evidence-based guidelines exist concerning the ideal treatment of angiosarcomas. Elec-
trochemotherapy (ECT) is an efﬁcient palliative treatment of cutaneous and subcutaneous tumornodules.
It consists of the combination of a cytotoxic drug and electroporation, using appropriate electrical param-
eters; destabilization of the membrane is reversible, ensuring a high survival of permeabilized cells and
the delivery of non-permeant molecules inside the cell.
CONCLUSION: Due to the rarity of the disease, prospective studies concerning adjuvant or neoadjuvant
therapy are limited and no evidence-based guidelines exist. The response to chemotherapy seems to be
poor. Treatment with ECT in addition to systemic chemotherapy achieves a complete response in all the
lesions and improving patient body image perception.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Case report
In February 2011, we observed a 76-year-old woman with a
painful, violet, multi-nodular mass occupying the entire left breast
along with small nodules in right breast skin (Fig. 1). The lesion
had rapidly enlarged. At the anamnesis she previously underwent
breast-conservative surgery and axillary dissection for invasive
ductal carcinoma of the left breast in 2003. Immunohistochemical
analysis revealed estrogen and progesterone receptor positivity.
The tumor was classiﬁed as pT1 pN0 M0 G2 StageI, according
to the UICC–TNM classiﬁcation. She received radiotherapy as fol-
lows: 50Gy in 25 fractions of 200 cGy/daily with boost of 10Gy in
5 fractions of 200 cGy/daily.
No adjuvant chemotherapy was given. She received adjuvant
hormone therapy (Tamoxifene 20mg daily for two years and Anas-
trozole for three years). The patient did not suffer from chronic
lymphedema.
Abbreviations: ECT, electrochemotherapy;RIA, radiation inducedangiosarcoma;
RECIST, response evaluation criteria in solid tumors; ESOPE, European Standard
Operating Procedures Of Electrochemotherapy.
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In February 2007, the patient noticed a subcutaneous lesion
of about 3 cm in diameter at the left breast. An excisional biopsy
was performed. Histopathological examination revealed a vascular
structure lined by atypical cells with hyperchromatic nuclei and
eosinophilic cytoplasm.
Tumor cells were positive for CD34 and Vimentin and negative
for SMA and CKP, indicating an endothelial origin.More than 90% of
the cells in the solid componentwere positive for Ki67. The diagno-
sis of capillary-like grade-II angiosarcoma of the breast was made.
No metastases were found at total body CT scan. Serum tumor
marker levels were within normal limits. Adjuvant chemotherapy
was not prescribed.
In February 2011, the cancer recurred replacing entirely the
lower quadrants of the breast. It was violaceous, hemorrhagic
and measured 12×9 cm. A total left mastectomy was performed,
followedby repair of the skin defect using adorsal skin graft.Micro-
scopically, the lesion was composed of intricate vascular channels
surrounding and invading the breast lobules. Numerous mitoses
were observed. Immunohistochemistry showed CD31 and CD34
positivity. This was consistent with the diagnosis of capillary- and
papillary-like grade-II angiosarcoma of the breast. A total body CT
scan was repeated and showed no metastases.
The cancerwas completely removed, but threemonths later the
patient noticed a mass in her right breast with local relapse with
http://dx.doi.org/10.1016/j.ijscr.2015.06.004
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Multi-nodular mass occupying the entire left breast.
multifocal nodes in her left chest wall. A right mastectomy was
performed. The lesions into the chest wall were not amenable for
surgery.
The left chest wall was treated with local ECT with intravenous
bleomicin (Fig. 2). Treatmentwas performed according to the stan-
dard operating procedures for ECT (ESOPE – European Standard
Operating Procedures of Electrochemotherapy) [9] under general
anesthesia. Bleomycin 15000 IU/m2 was injected intravenously.
Pulses were delivered 8–30min after injection [10]. Electric pulses
were delivered using a square wave electroporator (IGEA, Carpi,
Italy). The applied voltagewas 1.0 kV/cm for needle electrodes, and
pulses were applied at 5kHz.
Sixmonths later the patient developedmultiple abdominal skin
nodulesnot suitable for surgical treatment. Another treatmentwith
ECT was performed (Fig. 3). Response rate was evaluated similarly
to the response evaluation criteria in solid tumors (RECIST version
1.0) [11]. Overall, 51 lesion were treated at ﬁrst and second thera-
Fig. 2. Electrochemoterapy of multiple thoracic skin nodules, the needles are
inserted into the lesion and electric pulses are delivered after intravenous injection
of bleomycin.
Fig. 3. Multiple neoplastic abdominal skin nodules.
peutic session of ECT with median (range) diameter of 15 (10–25)
mm. Considering all treated nodules (N=51), 51(100%) had com-
plete response, as assessed atphysical examination (Fig. 4).
No detectable metastatic disease was found. Adjuvant
chemotherapy with Doxorubicine(40mg/m2) was prescribed,
repeated every 4 weeks for 6 cycles aiming to prevent distant
recurrences. The patient is currently well with no recurrence 18
months after the operation.
2. Discussion
Angiosarcomas are rare malignant tumors which arise from
endothelial cells lining vascular channels. Breast angiosarcomas
can be either observed as primary neoplasms or, more commonly,
in upper limb lymphedema as a result of breast conservative
surgery and radiotherapy for breast carcinoma [1–10]. Radiation-
induced angiosarcoma (RIA) was ﬁrst reported in the literature in
1929 [11], and is a common form of angiosarcoma. The diagnostic
criteria for RIA include: a previous history of radiotherapy, peak
incidence between 5 and 10 years, development of sarcomawithin
a previous irradiated ﬁeld, histology conﬁrmation .RIAs are charac-
Fig. 4. Complete response and no relapses is observed 18months after
Eletrochemoterapy.
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terized by their aggressive nature andmost of them are high-grade
tumors. The prognosis is poor and local recurrence rates reaches
70% after mastectomy [11–13]. RIAs often present as cutaneous or
subcutaneous painless, ﬂat or nodular, bluish or purplish lesion/s,
similar to benign angiomas, small hematomas, or atypical telang-
iectasia [10].
Due to the rarity of the disease, prospective studies with regard
to adjuvant therapy are limited and no evidence-based treatment
guidelines exist [12,13]. Skin metastases from solid tumors behave
ina similar fashion, irrespectiveof the tumorentity [14]. The lesions
may be distressing for the patient, due to their visibility or symp-
toms such as weeping, bleeding, and pain.
ECThas emergedas aneffective local treatment forpatientswith
cutaneousandsubcutaneous tumornodules. It combines theeffects
of a cytotoxic intravenous drug and electroporation by means of
electric ﬁelds, which temporarily increase the permeability of cell
membrane allowing the direct diffusion of the drug within malig-
nant cells [4,17–19].
ECT has recently been proposed as a novel, complementary
therapeutic option for the control of superﬁcial disease. This ther-
apeutic approach is a feasible alternative in case of inoperable
tumors, located in pre-irradiated areas and in areas resistant to
chemotherapy [7,17,18,20]. Since recurrence and survival rate of
angiosarcomas mainly depend on wide excision margins, safety
histological margins of at least 5 cm are recommended, but may
require extended excisions, which are not always possible. Due to
the rarity of thedisease, prospective studies concerning adjuvant or
neoadjuvant therapy are limited and no evidence-based guidelines
exist. The response to chemotherapy seems to be poor. However,
anthracyclines are effective agents for soft tissue sarcomas and are
mainly used as ﬁrst-line therapy. In this case local treatment was
combined with doxorubicine [15,16].
In our patient, presenting with unresectable and extended
angiosarcomas, treatment with ECT in addition to systemic
chemotherapy was likely to have signiﬁcantly boosted the efﬁcacy
of the intravenous drug at the sites of angiosarcomas, achieving a
complete response in all the lesions and improving patient body
image perception. Neither symptomatic nor asymptomatic recur-
renceswere observed at 18-months follow-up, suggesting that ECT
is a promising tool in the palliative care of patients presentingwith
angiosarcomas after breast surgery.
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